Compare AbCellera Biologics Inc (ABCL) vs Blackstone Inc (BX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Blackstone Inc — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Blackstone Inc trades at $118.21 (market cap $147.67B). The key difference: Blackstone Inc is far larger — about 62.8× AbCellera Biologics Inc's market cap, and Blackstone Inc pays a 4.11% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BX | |
|---|---|---|
Market Cap | $2.35B | $147.67B |
Sector | Health | Financials |
52-Week High | $8.12 | $188.68 |
52-Week Low | $2.78 | $102.12 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 4.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BX trades at $120.88, down 1.51% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $12.41B in 2025, with a net income margin of 24.27% and robust ROE of 37.36%. Recent news highlights strategic moves in energy transition, AI data centers, and credit markets, including a $30B Japan AI investment plan reported by Reuters on June 23, 2026.
Outlook remains positive with a consensus price target of $150.78, implying 25% upside, supported by 62% analyst buy ratings. Risks include execution of large investments and market volatility, but fundamentals and institutional sentiment favor long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →
